Diagnostics & Tech
Our High Complexity CLIA and COLA accredited lab is active in COVID-19 testing, RT-PCR testing and serology testing with the capacity to process 4,000 RT-PCR test specimens per day.
In 2020, Empower re-purposed its pre-existing diagnostic testing to serve the massive demand for national COVID testing in the US.
- Venue tracing
- Frequent testing with rapid results
- Real-time reporting to ensure the travel bubble provides end-to-end protection
RESEARCH & DEVELOPMENT
KAI Medical completed clinical trials, laboratory analysis and validation of the API Pharma Rapid COVID-19 Antigen test submitted to the FDA for approval for use in the US and has submitted a Health Canada application.
The tests are developed with the highest of standards and meet CDC, Health Canada and FDA guidelines for distribution and sale.
Demand for this novel test is high and will be sold through partners serving the public sector and the medical community throughout North America.
Kai Medical has developed a Saliva PCR test for at home specimen collection to detect COVID-19 and Influenza A/B with end user comfort in mind.
Even once we reach a post-COVID-19 world, we strongly believe that telemedicine is the future of delivery of healthcare. Currently, about 59 million Americans reside in health professional-shortage areas, which are rural and urban areas with shortages of primary care providers. Telemedicine allows patients living in both rural and urban areas to access healthcare when they need it. It also has been used successfully to improve patient access to medical care while reducing healthcare costs.
Empower currently provides its telemedicine platform to patients in Washington State, Oregon, and Arizona, however, we plan to roll out a nationwide telemedicine platform to provide continuity of care for patients who cannot physically make the trip to our clinics.